They say LH’ers because they really don’t have a clue
They say LH’ers because they really don’t have a clue as to what is going on. Stroking Dr Patent stealer because people want to portray him as the expert in LH’ers. When the FDA didn’t pay attention to him on the 4 dose trial we wanted in the CD-12 trial. Dr JL wanted that 4 dose protocol and begged for it. Dr Patent stealer had no impact with the FDA as our paid consultant and sitting in on the Zoom meetings. He was basically useless to us in trial design and the FDA must of thought he was out of line in his beliefs because they disregarded our requests and the self proclaimed LH’ers expert didn’t have one bit of influence. They must of thought he was arrogant like many do. Sometime arrogance rubs people the wrong way and that is my contention of what happened with Dr. Patent stealer. Does the FDA even like him?
To dismiss the Brazil trials is total blindness to what would be most likely quickest to and our first approvals. Just understanding the difference from these trials from our last trials tells you that we have made changes to our trials and provided primary endpoints that are achievable. Mainly because we have already achieved these endpoints or corrected the reason we have not. These are the results of learning from our previous CD-10 & CD-12 trials.
The 13d group would possibly stop all trials and just focus on one trial at a time. This is what they started to promote when they first started this proxy group and I have not heard anything to change that projection of how they will deal with our current trials. Will they continue the trials or stop them and focus on just Long Haulers. Are they still that arrogant?
I like that we are tackling multiple super huge block busters indications at the same time. We have multiple shots on goal as they say. Having all your eggs in one basket isn’t good business or good foresight for any business. Betting on Dr. Patent stealer isn’t something we should bet on when his immediate past has been so questionable. I have no trust in this self enrichment motivated group to help our company. If you see it differently… you can’t be paying close enough attention to what is going on. We are better off with our current management team. Our current managements business plan is far superior to the 13d groups remedial plan of pulling back and stopping all trials. Who is that stupid? That’s the real question. How can anyone follow the 13d group when they have offered us nothing in comparison to our current business plan.
All this should be decided in 3 more days when the judge rules they are not even on the ballot. Bylaws are laws to a judge. The judge should will rule by the bylaws.
10
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...
Continue Reading
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...
Continue Reading
Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Top 5 Most Recently Viewed Articles
Critical Alert for Investors in Easterly ROCMuni Bond Fund Attention investors! There’s an important deadline approaching concerning legal actions related to the Easterly ROCMuni High Income Municipal Bond Fund. If you have experienced losses, now is the time to stay informed and act. Understanding the Situation Recently, the Easterly ROCMuni High Income Municipal Bond...
Continue Reading
Veralto's Quarterly Dividend Announcement Veralto (NYSE: VLTO), a leading name in water and product quality solutions, has announced a quarterly dividend of $0.09 per share. This decision underscores Veralto's unwavering commitment to its shareholders and its ongoing financial health. Understanding Dividend Payments Dividends often indicate a company's financial...
Continue Reading
BioLineRx Continues to Build Momentum with Financial Stability BioLineRx Ltd. (NASDAQ: BLRX), a prominent biopharmaceutical company dedicated to advancing treatments in oncology and rare diseases, has reported robust financial results and significant progress in its operational endeavors. The company is pursuing new innovative avenues for pipeline expansion while ensuring...
Continue Reading
Blues Expands Its Partnership Network Recently, the Blues Partner Network has marked a significant milestone by welcoming more than fifty accredited partners. This innovative initiative focuses on easing the connections between sensors and the analytics solutions essential for various businesses. The advantages brought by Blues' products streamline how devices connect to...
Continue Reading
Lamarr.AI Secures $1.1 Million to Improve Building Solutions Lamarr.AI has recently garnered substantial attention, raising $1.1 million in a pre-seed funding round aimed at advancing their innovative building diagnostics technology. Supported by notable investors, including Hazelview Ventures, milemark·capital, and Newlab, Lamarr.AI is positioning itself as a leader in...
Continue Reading